Relationships of Total and Domain-Specific Moderate-to-Vigorous Physical Activity with All-Cause and Disease-Specific Mortality
-
- HIROYUKI KIKUCHI
- Department of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo, JAPAN
-
- SHIGERU INOUE
- Department of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo, JAPAN
-
- HIKARU IHIRA
- Division of Cohort research, National Cancer Center Institute for Cancer Control, Tokyo, JAPAN
-
- HIROYASU ISO
- Institute for Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, JAPAN
-
- NORIE SAWADA
- Division of Cohort research, National Cancer Center Institute for Cancer Control, Tokyo, JAPAN
書誌事項
- 公開日
- 2023-10-25
- 資源種別
- journal article
- DOI
-
- 10.1249/mss.0000000000003331
- 公開者
- Ovid Technologies (Wolters Kluwer Health)
この論文をさがす
説明
<jats:title>ABSTRACT</jats:title> <jats:sec> <jats:title>Purpose</jats:title> <jats:p>This study aimed to investigate the relationships of moderate-to-vigorous physical activity (MVPA) with all-cause and disease-specific mortality. We also investigated how the association between MVPA at leisure time (LT-MVPA) and health outcomes differs at different MVPA at work (WT-MVPA) levels.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>The 81,601 community-dwelling Japanese persons age 50–79 yr who responded to a questionnaire in 2000–2003 were followed until 2018. Cox proportional hazard model was used to examine the association of total MVPA with risks of all-cause, cancer, heart disease, stroke, and respiratory disease mortality. Then, we compared the mortality risk according to the tertile of LT-MVPA, stratified by the tertile of WT-MVPA.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>During the 15.1 yr of average follow-up, 16,951 deaths were identified. Even total MVPA below the recommended volume (i.e., 0.1–1.49 MET·h·d<jats:sup>−1</jats:sup>) was associated with 11% to 24% reductions in all-cause (hazard ratio [HR], 0.89; 95% confidence interval [CI], 0.82–0.96) and heart disease mortality (HR, 0.76; 95% CI, 0.61–0.94), compared with no MVPA at all. The further reduced risks were seen in MVPA up to 10 MET·h·d<jats:sup>−1</jats:sup>. The inverse association between LT-MVPA and mortality risks was more evident at lower WT-MVPA, which was also inversely associated with the risks.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Health benefits were observed at low levels of MVPA and up to 10 MET·h·d<jats:sup>−1</jats:sup>, although the fine threshold for excessive MVPA was not clear. LT-MVPA had distinct health benefits especially for persons with lower WT-MVPA.</jats:p> </jats:sec>
収録刊行物
-
- Medicine & Science in Sports & Exercise
-
Medicine & Science in Sports & Exercise 56 (3), 520-527, 2023-10-25
Ovid Technologies (Wolters Kluwer Health)
